in Barcelona (Spanien)

Onkologe, Gastroenterologe

Dr. Jaime De La Torre Rojo ist Facharzt für Orthopädie und Traumatologie. Er ist bekannt für seine fortgeschrittenen arthroskopischen Techniken. Seine Forschung wurde in der Revista Iberoamericana de Cirugía de la Mano veröffentlicht. Er untersucht unter anderem Operationsergebnisse bei älteren Patienten mit distalen Radiusfrakturen.

Dr. De La Torre Rojo behandelt Gelenkfrakturen des Radius und Skaphoids sowie Bandverletzungen des Karpus. Zudem führt er komplexe Knieeingriffe durch, darunter Kniearthroskopien, Rekonstruktionen des vorderen Kreuzbands, Knieprothesen, Kniearthroplastiken und unikompartimentelle Knieprothesen. Seine klinische Arbeit und Forschung machen ihn zu einem anerkannten Experten auf seinem Gebiet.

Onkologe, Spezialist für Hautkrebsbehandlung

Dr. Moises graduierte 1992 an der Medizinischen Fakultät der Universidad Nacional de Tucumán mit einem Abschluss in Medizin und Chirurgie. Er spezialisierte sich auf Nephrologie und verteidigte 1995 seine Doktorarbeit. Außerdem erhielt er ein Forschungsstipendium der Universidad Nacional de Tucumán en Médico. Von 1995 bis 2000 war er Facharzt in der Transplantationsabteilung des Krankenhauses Clínic de Barcelona und von 2004 bis 2009 leitender Facharzt der Teknon-Abteilung für Innere Medizin. Derzeit ist er Leiter dieser Abteilung und Mitglied verschiedener Organisationen, darunter die spanische Gesellschaft für Nephrologie, die spanische Gesellschaft für arterielle Hypertonie und die katalanische Gesellschaft für arterielle Hypertonie.

Allgemein- und Verdauungstraktchirurg mit Expertise in minimal-invasiver laparoskopischer Chirurgie. Hat Positionen als Associate Clinical Lecturer und Dozent an der Medizinischen Fakultät der Universität von Navarra innegehabt. Mitglied der Spanischen Chirurgenvereinigung, der Spanischen Gesellschaft für Adipositaschirurgie und der Europäischen Vereinigung für endoskopische Chirurgie.

Strahlenonkologe

Entdeckte die genetische Ursache eines seltenen Syndroms, das plötzlichen Herztod verursacht und später als Brugada-Syndrom bezeichnet wird.
Hat über 25.000 Herzablationen durchgeführt.
Hat über 350 wissenschaftliche Arbeiten zur Kardiologie veröffentlicht.
Hat über 200 Spezialisten ausgebildet.
Hat jährliche Besuche in Afrika, um Kinder mit Herzrhythmusstörungen zu behandeln.

Dr. Jose Maria Raventos ist Chirurg mit 49 Jahren Erfahrung. Er ist spezialisiert auf Allgemein-, Bauch-, Endokrin- und Schilddrüsenchirurgie und bekannt für seine fortgeschrittenen laparoskopischen Fähigkeiten. Dr. Raventos verfügt zudem über große Erfahrung in der Schilddrüsenchirurgie, auch bei komplexen Schilddrüsenkrebsfällen.

Er hat wichtige Beiträge zur chirurgischen Forschung und Ausbildung geleistet, zahlreiche wissenschaftliche Artikel veröffentlicht und ist in mehreren Fachverbänden aktiv. Dr. Raventos erhielt seine medizinischen Abschlüsse an der Universität Barcelona und der University of Minnesota. Seine Facharztausbildung absolvierte er am Rotkreuz-Krankenhaus Barcelona und an der Mayo Clinic in Rochester. Er ist Gründungsmitglied der Fakultät des Teknon Medical Center und der Gruppe Surgical Associate Surgeons.

Dr. Lana Bijelic ist eine Fachärztin für onkologische Chirurgie mit Schwerpunkt auf Peritonealkarzinose. Seit 2019 gehört sie zum Carcinomatosis Surgical Group am Teknon Oncology Institute. Sie wurde bei Prof. Paul Sugarbaker am Washington Hospital Center ausgebildet und bringt umfassende Expertise in ihr Team ein.

Dr. Bijelic war Forschungsleiterin am Inova Fairfax Hospital und außerordentliche Professorin an der Virginia Commonwealth University sowie der Georgetown University. Sie ist aktives Mitglied des American College of Surgeons und der Society of Surgical Oncology.

Im Laufe ihrer Karriere erhielt Dr. Bijelic zahlreiche akademische Auszeichnungen, darunter mehrere Preise für chirurgische Exzellenz und Spitzenleistungen in der Forschung. Sie ist bekannt für ihre Führungsqualitäten und bedeutenden Beiträge zur chirurgischen Onkologie.

Dr. Ellen Christiaanse ist Expertin für alternative Heilmethoden. Sie verbindet evidenzbasierte Ansätze mit ganzheitlichen Praktiken. Sie promovierte in Informationssystemen am MIT und hat einen Master in Organisationspsychologie.

Dr. Christiaanse ist zertifizierte Reiki-Meisterin, Yin-Yoga-Lehrerin, Klangtherapeutin und pferdegestützte Coachin. Sie hat über 100 Gesundheitsretreats geleitet, darunter Yoga-, Meditations-, Detox- und Frauenprogramme. Sie ist bekannt für innovative Heilmethoden und ihr Engagement für integrative Gesundheit. Ihre Kundenzufriedenheit liegt bei über 95 %.

Dr. Karin P. Q. Oomen, MD PhD

Consultant ENT Surgeon

www.andsurgeons.com

Date of Birth: 13 August 1977

Education

Biology, University of Utrecht — Sep 1995 – Sep 1996

Doctoral Degree in Medicine, University of Utrecht — Sep 1996 – Dec 2001

M.D., School of Medicine, University of Utrecht — Dec 2001 – Dec 2003

Junior Staff Teacher, Dept. of Anatomy, UMC Utrecht — Jun 2004 – Aug 2005

Senior House Officer, ENT Surgery, UMC Utrecht — Aug 2005 – Jan 2006

Residency, ENT Surgery, UMC Utrecht/Wilhelmina Children's Hospital — Feb 2006 – Feb 2011

PhD, Dept. of Anatomy & ENT Surgery, University of Utrecht — Feb 2011 – May 2011

Thesis: Anatomical and clinical appraisal of the pterygopalatine ganglion. Defended: 27 May 2011

Certifications

ECFMG Certification — 1 May 2012

Step I: 203/84

Step IIa – Clinical Knowledge: 223/80

Step IIb – Clinical Skills: Pass

Fellowship

Paediatric Otolaryngology, Weill Cornell Medical College, New York, USA — Aug 2011 – Aug 2013

Mentors: Dr. Robert F. Ward, Dr. Vikash K. Modi

Professional Experience

Current Positions (since 2022)

Consultant ENT Surgeon & Owner, ANDSURGEONS, Andorra

Consultant ENT Surgeon, Clínica Omega Zeta & Clínica SOM Salut, Andorra

Consultant ENT Surgeon, Doctus (La Seu d'Urgell), Avantmedic (Lleida), Centro Medico Teknon (Barcelona), Spain

Locum Consultant ENT Surgeon, Medinet, Portland Clinical, Imperial College London (Honorary Contract)

Previous Roles

Paediatric Otolaryngologist, UMC Utrecht/Wilhelmina Children’s Hospital — Feb 2014 – Feb 2016

Specialized in voice, airway, cleft palate, 22q11, and laryngotracheal surgery

Researcher, Access to Medicine Foundation, Amersfoort — Feb 2017 – Apr 2017

Lead author of publication on cancer care access in LMICs

Consultant ENT Surgeon, Elkerliek Hospital, Helmond, NL — May – Jun 2017

Consultant ENT Surgeon, Queen Alexandra Hospital, Portsmouth, UK — Sep 2017 – Dec 2020

Licensure

United Kingdom: GMC #7511829 – Fully Registered, Specialist Registration

Netherlands: BIG #49061371701 – Physician (since Dec 2023)

Netherlands: RGS #1910932 – Otolaryngologist (since Feb 2011)

Spain: COMB #65907 (Barcelona)

Andorra: RPS #03255, Collegiat #913

Languages

Dutch: Native

English: Full Professional Proficiency

Spanish, German: Professional Working Proficiency

French: Limited Working Proficiency

Identification Numbers

NL Social Security: 170621303

UK NI Number: SZ758509B

Spain NIE: Z1396887-X

Andorra NIA: 387493R

Medical Missions

Cleft lip and palate repair, Antigua, Guatemala — MMFC — Jun 2012

Publications

Selected from 26 total; full list available on request

1. Oomen KP, et al. Effect of adenotonsillectomy on middle ear status in children. Laryngoscope 2005.

2. Oomen KP, et al. Sluder’s neuralgia: a trigeminal autonomic cephalalgia? Cephalalgia 2010.

3. Oomen KPQ, et al. A previously undescribed branch of the pterygopalatine ganglion. Am J Rhinol Allergy 2011.

Dr. Antonio Alcaraz ist ein spanischer Uro-Onkologe und Transplantologe mit über 30 Jahren Erfahrung und 500 erfolgreichen Operationen, der sich auf die Behandlung von Prostatakrebs, Nieren-, Blasen- und anderen Pathologien des Urogenitalsystems mit minimalinvasiven und Robotersystemen sowie spezialisiert hat angeborene Pathologien bei Kindern. Er ist Mitglied mehrerer renommierter urologischer Gesellschaften.

Dr. Pierluigi Minicozzi ist zertifizierter Hatha-Yoga-Lehrer. Seine Ausbildung absolvierte er 2019 bei Alliance Yoga in Rishikesh, Indien. Er hat in Italien und Spanien unterrichtet und leitet Kurse auf Festivals und in Retreat-Zentren.

Dr. Minicozzi verbindet in seinem Unterricht verschiedene spirituelle Traditionen und ganzheitliche Praktiken. Sein Fokus liegt darauf, Körper, Geist und Emotionen in Einklang zu bringen. Er fördert Selbstwahrnehmung und Wohlbefinden und engagiert sich für eine transformative Yoga-Ausbildung.

CURRICULUM VITAE

VOLKERT B. WREESMANN MD PhD

Consultant Otolaryngologist

Oncologic Head and Neck Surgeon

Thyroid and Parathyroid Surgeon

Facial Plastic Surgeon

Principal Positions

• Centro Medico Teknon, Barcelona, Spain

Chairman, Department of Otolaryngology-Head and Neck Surgery

July 1st 2024 – present

• Juaneda, Ciutadella Menorca, Spain

Consultant Otolaryngologist-Head and Neck Surgeon

January 2025 – present

• Avantmedic, Lleida, Spain

Consultant Otolaryngologist-Head and Neck Surgeon

July 1st 2024 – present

• Clinica Omega Zeta, Andorra

Consultant Otolaryngologist-Head and Neck Surgeon

March 1st 2022 – present

• University Hospitals Dorset NHS Foundation Trust

Consultant Otolaryngologist-Head and Neck Surgeon

August 1st 2021 – October 1st 2023

• Oxford University Hospitals NHS Foundation Trust

Honorary Consultant Otolaryngologist-Head and Neck Surgeon

May 1st 2021 – April 30th 2024

• Portsmouth Hospitals University NHS Trust, Portsmouth, UK

Consultant Otolaryngologist-Head and Neck Surgeon

July 18th 2016 – April 30th 2021

• Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

Consultant Otolaryngologist-Head and Neck Surgeon

November 7th 2015 – May 31st 2016

• Heart of England NHS Trust, Birmingham, UK

Consultant Otolaryngologist-Head and Neck Surgeon

March 1st 2015 – October 31st 2015

• University Medical Center Utrecht, Netherlands

Consultant Otolaryngologist-Head and Neck Surgeon

November 1st 2013 – June 1st 2014

Memberships

• American Head and Neck Society – Member

Netherlands Academy of Otolaryngology - Member

Professional Licences

• United Kingdom

GMC Certification

Fully Registered Medical Practitioner with Specialist Registration with a License to Practice

Registered: 02/02/2015

GMC # 7499626

• United States of America

New York State Department of Health

New York State Education Department

Registered: July 2011

License# P80949

Physician

• Netherlands

Dutch Ministry of Health (BIG Registration)

BIG Registered: 22-06-2005

BIG #19063373601

Physician

Dutch Specialist Board (RGS)

RGS registered: 01-02-2011

RGS #1911979

Otolaryngology-Head and Neck Surgeon

• Spain

Collegi de Metges de Barcelona

COMB: 63638

• Andorra

Collegi de Metges d’Andorra

RPS: 03098

COMA: 876

Education

• Memorial Sloan-Kettering Cancer Center

Surgical Fellowship, Head and Neck Surgery

New York, New York, USA

August 1st 2011 - July 31st 2013

600 bed dedicated cancer center

Performed 1200 major oncologic head and neck resections in 2 years

• United States of America ECFMG Certification

United States Medical Licensing Examination (USMLE)

Certification: June 22nd, 2010

Scores: 

   Step I: 244/99 

   Step IIa-Clinical knowledge: 227/94

   Step IIb-Clinical Skills: PASSED

   Step III: 206/85

• Netherlands Cancer Institute

Surgical Fellowship, Head and Neck Surgery

Amsterdam, The Netherlands

February 1st 2011 - July 31st 2011

Specialized Head and Neck Cancer Surgery Department

200 bed hospital

• Amsterdam University Medical Center/Netherlands Cancer Institute

Residency Training, Otolaryngology-Head and Neck Surgery

Amsterdam, the Netherlands

February 1st 2006 – January 31st 2011

• University of Amsterdam School of Medicine

Medical Doctor (MD)

Amsterdam, the Netherlands

December 2002 - January 28th 2005

• University of Amsterdam

Doctor of Philosophy (PhD), Molecular Biology

Amsterdam, the Netherlands

Thesis title: Molecular-cytogenetic characterization of head and neck cancer

December 2nd, 2004

• Erasmus University School of Medicine

Doctoral Degree in Medicine

Rotterdam, the Netherlands

September 1994 - November 17th, 1998

Research Training

• Memorial Sloan-Kettering Cancer Center

Laboratory of Epithelial Cancer Biology, Head and Neck Service, Department of Surgery, New York, New York, USA

Research Fellowship in Molecular Oncology

Supervisors: Dr. Bhuvanesh Singh MD, PhD and Dr. Jatin P. Shah, MD, FACS

March 1st 1999 - September 30st 2002

• University of California San Francisco (UCSF)

Department of Otolaryngology-Head and Neck Surgery, San Francisco, California, USA

Post-doctoral Research Fellowship in Head and Neck Oncology

Supervisors: Dr. Steven Wang MD And Prof David Eisele MD

February 2005 - January 2006

Academic Activities

University of Amsterdam

Doctorate Examination Committee member

• September 17th, 2013 - PhD Candidate: Dr. I.J. Nixon (United Kingdom)
• October 17th 2014 - PhD Candidate: Dr. J. Pramana (Netherlands)
• November 17th 2015 - PhD candidate: Dr. H. van Monsjou (Netherlands)
• December 11th 2018 - PhD Candidate: Dr. Tihana Ibrahimpasic (United States)
• January 18th, 2021 - PhD Candidate: Dr. Laura Wang (Australia)
• June 2nd, 2021 - PhD Candidate: Dr. Caroline Verhagen (Netherlands)

Conference Faculty

• Advanced Laryngopharyngeal Cancer: Functional Preservation and Rehabilitation, Portsmouth, June 25th - 26th, 2020 (postponed due to COVID) - Chairman
• Functional Preservation and Rehabilitation after Treatment for Advanced Laryngeal Cancer, Portsmouth, March 14th - 15th, 2019 - Chairman
• Portsmouth Parathyroid Conference, Portsmouth, December 14th 2018 – Chairman

Editorial Roles

• European Journal of Surgical Oncology

Associate Editor

January 1st 2023 – present

• European Journal of Surgical Oncology

Guest Editor

March issue 2018, Volume 44, Issue 3, p275-378 - Special issue on thyroid cancer management

• Journal of Oral Pathology and Medicine

Guest Editor

November issue 2021, Volume 51, Issue 10 - Special issue on vascular malformations and tumors of the head and neck

• Scientific Journal Reviewer

Oral Oncology, European Journal of Surgical Oncology, Journal of Surgical Oncology, Head and Neck, International Journal of Cancer

• Scientific Project and Grant Reviewer

Netherlands: Dutch Cancer Society

France: Institute National du Cancer

Awards

• New York Head and Neck Society

Annual Meeting, New York, NY, March 2002

Title of study presented: “MUC1 is a target if 1q amplification and pertains a grave clinical prognosis in papillary thyroid cancer”

Invited Lectures

• European Society of Surgical Oncology meeting, Krakow, 2016
• Barcelona Society of Neurosurgery, Annual Meeting, Baqueira, Spain, February, 2017
• University of Edinburgh, Department of Otolaryngology Academic Conference, March 17th 2017
• Medilex: Performance of Medical Specialists, Zeist, Netherlands, November 9th 2017
• Medilex: Performance of Medical Specialists, Driebergen, Netherlands, October 11th 2017
• Wessex Head and Neck and Thyroid Network Education Day, May 3rd, 2017
• Portsmouth Parathyroid Conference, Portsmouth, UK, December 14th 2018
• Global Post-laryngectomy Rehabilitation Academy, Portsmouth, UK, March 14th 2019
• Health Care Quality Conference, Beverwijk, Netherlands, March 25th, 2019

Published Research Reports

• The growing precision of diagnostic pathways in thyroid nodule evaluation. 

Bekker J, Wreesmann VB. 

Eur J Surg Oncol. 2025 Jan;51(1):109374.

• Special issue: Management of vascular tumors and malformations of the head and neck. 

Oomen KPQ, Brennan PA, Wreesmann VB. 

J Oral Pathol Med. 2022 Nov;51(10):829.

• Angiosarcomas of the head and neck: Impact of large data analysis on clinical management.
•  
• Wreesmann VB, Oomen KP, Brennan PA.

J Oral Pathol Med. 2022 Nov;51(10):904-910.

• Current classification of vascular anomalies of the head and neck. 

Oomen KPQ, Wreesmann VB. 

J Oral Pathol Med. 2022 Nov;51(10):830-836.

• A novel classification of carotid body tumors.

Wreesmann VB, Nixon IJ. 

Eur. J. Surg. Oncol. May, 2021

• Management of the contralateral central neck in differentiated thyroid cancer: A contentious issue. 

Shaha AR, Tuttle RM, Wreesmann VB. 

Eur. J. Surg. Oncol. 2021 Apr;47(4):717-719.

• Improvement of oral cancer screening quality and reach: The promise of artificial intelligence.
•  
• Kar A, Wreesmann VB, Shwetha V, Thakur S, Rao VUS, Arakeri G, Brennan PA.

J Oral Pathol Med. 2020 Mar 11

• The risk-benefit ratio of chemoradiation treatment in head and neck squamous cell carcinoma: value of extranodal spread and margin status. 

Ammar M, Wreesmann VB. 

Journal of ENT Masterclass, Yearbook 2018, Volume 11, Nr. 1, December 1st, 2018

• Nasal obstruction secondary to an inverted midline supernumerary tooth. 

Jones L, Hilton JM, Heyman J, Viswanathan H, Wreesmann VB, Hayes SM. 

Ann R Coll Surg Engl. 2019 Jan;101(1)

• Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma. 

Verhagen CVM, Vossen DM, Borgmann K, Hageman F, Grénman R, Verwijs-Janssen M, Mout L, Kluin RJC, Nieuwland M, Severson TM, Velds A, Kerkhoven R, O'Connor MJ, van der Heijden M, van Velthuysen ML, Verheij M, Wreesmann VB, Wessels LFA, van den Brekel MWM, Vens C. 

Oncotarget. 2018 Apr 6;9(26):18198-18213.

• Complete nasal obstruction secondary to pacemaker insertion. 

Jones TL, Wreesmann VB, Nilssen E, Hilton J, Hayes SM. 

Ann R Coll Surg Engl. 2018 May;100(5)

• Optimization of the risk-benefit ratio of differentiated thyroid cancer treatment. 

Nasef HO, Nixon IJ, Wreesmann VB. Eur J Surg Oncol. 

2018 Mar;44(3):276-285. Review.

• The risk/benefit ratio of differentiated thyroid cancer treatment: Exploring treatment de-escalation. 

Wreesmann VB; on behalf of EJSO. 

Eur J Surg Oncol. 2018 Mar;44(3):275.

• Aggressive differentiated thyroid cancer. 

Janjua N, Wreesmann VB. 

Eur J Surg Oncol. 2018 Mar;44(3):367-377. Review.

• Role of extracapsular nodal spread and surgical margin status in defining high-risk head and neck squamous cell carcinoma and its treatment intensity. 

Wreesmann VB. 

International Journal of Head and Neck Surgery, April-June 2017; 8(2): 76-83.

• An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer.              

Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, Morris L, Vaisman F, Corbo R, Momesso D, Vaisman M, Carvalho A, Learoyd D, Leslie WD, Nason RW, Kuk D, Wreesmann V, Morris L, Palmer FL, Ganly I, Patel SG, Singh B, Tuttle RM, Shaha AR, Gönen M, Pathak KA, Shen WT, Sywak M, Kowalski L, Freeman J, Perrier N, Shah JP. 

Thyroid. 2016 Mar;26(3):373-80.

• Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma. 
•  
• Wreesmann VB, Katabi N, Palmer FL, Montero PH, Migliacci JC, Gönen M, Carlson D, Ganly I, Shah JP, Ghossein R, Patel SG.

Head Neck. 2016 Apr;38 Suppl 1:E1192-9.

• Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. 

Nixon IJ, Kuk D, Wreesmann V, Morris L, Palmer FL, Ganly I, Patel SG, Singh B, Tuttle RM, Shaha AR, Gönen M, Shah JP. 

Ann Surg Oncol. 2015 Jul 28.

• Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma.
•  
• Wreesmann VB, Nixon IJ, Rivera M, Katabi N, Palmer F, Ganly I, Shaha AR, Tuttle RM, Shah JP, Patel SG, Ghossein RA.

Thyroid. 2015 May;25(5):503-8.

• Head and neck squamous cell carcinoma in young patients.

van Monsjou HS, Wreesmann VB, van den Brekel MW, Balm AJ. 

Oral Oncol. 2013 Dec;49(12):1097-102.

• Oral and oropharyngeal squamous cell carcinomas in young patients: The Netherlands Cancer Institute experience. 

van Monsjou HS, M Lopez-Yurda, M. Hauptmann, Balm AJ, van den Brekel MM, Wreesmann VB. 

Head Neck. 2013 Jan;35(1):94-102.

• Oropharyngeal squamous cell carcinoma: a unique disease on the rise?

van Monsjou HS, Balm AJ, van den Brekel MM, Wreesmann VB. 

Oral Oncol. 2010 Nov;46(11):780-5.

• Closure of tracheoesophageal fistula with prefabricated revascularized bilaminar radial forearm free flap.

Wreesmann VB, Smeele LE, Hilgers FJ, Lohuis PJ. 

Head Neck. 2009 Jun;31(6):838-42.

• Clinical impact of molecular analysis on thyroid cancer management.

Wreesmann VB, Singh B. 

Surg Oncol Clin N Am. 2008 Jan;17(1):1-35.

Genetic abnormalities associated with chemoradiation resistance of head and neck squamous cell carcinoma. 

van den Broek GB, Wreesmann VB, van den Brekel MW, Rasch CR, Balm AJ, Rao PH. 

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4386-91.

• Association of CD44 V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer.

Wang SJ, Wreesmann VB, Bourguignon LY. 

Head Neck. 2007 Jun;29(6):550-8.

• Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma.
•  
• Wreesmann VB, Estilo C, Eisele DW, Singh B, Wang SJ.

ORL J Otorhinolaryngol Relat Spec. 2007;69(4):218-25. Epub 2007 Apr 4.

• Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
•  
• Saltman B, Singh B, Hedvat CV, Wreesmann VB, Ghossein R.
•  
• Surgery. 2006 Dec;140(6):899-905; discussion 905-6.

• Repetitive endoscopic sinus surgery failure: a role for radical surgery?

Videler WJ, Wreesmann VB, van der Meulen FW, Knegt PP, Fokkens WJ. 

Otolaryngol Head Neck Surg. 2006 Apr;134(4):586-91.

• MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas.
•  
• Patel KN, Maghami E, Wreesmann VB, Shaha AR, Shah JP, Ghossein R, Singh B.
•  
• Surgery. 2005 Dec;138(6):994-1001; discussion 1001-2.

• Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities.

Wreesmann VB, Singh B. 

J Oral Pathol Med. 2005 Sep;34(8):449-59. Review.

• Molecular profiling of tumor progression in head and neck cancer.
•  
• Belbin TJ, Singh B, Smith RV, Socci ND, Wreesmann VB, Sanchez-Carbayo M, Masterson J, Patel S, Cordon-Cardo C, Prystowsky MB, Childs G.
•  
• Arch Otolaryngol Head Neck Surg. 2005 Jan;131(1):10-8.

• Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck.

Wreesmann VB, Shi W, Thaler HT, Poluri A, Kraus DH, Pfister D, Shaha AR, Shah JP, Rao PH, Singh B. 

J Clin Oncol. 2004 Oct 1;22(19):3965-72.

• Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity.

Wreesmann VB, Ghossein RA, Hezel M, Banerjee D, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B. 

Genes Chromosomes Cancer. 2004 Aug;40(4):355-64.

• Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker.

Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R, Singh B. 

Cancer Res. 2004 Jun 1;64(11):3780-9.

• Genetic abnormalities associated with nodal metastasis in head and neck cancer.

Wreesmann VB, Wang D, Goberdhan A, Prasad M, Ngai I, Schnaser EA, Sacks PG, Singh B. 

Head Neck. 2004 Jan;26(1):10-5.

• Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients.
•  
• Kutler DI, Wreesmann VB, Goberdhan A, Ben-Porat L, Satagopan J, Ngai I, Huvos AG, Giampietro P, Levran O, Pujara K, Diotti R, Carlson D, Huryn LA, Auerbach AD, Singh B.
•  
• J Natl Cancer Inst. 2003 Nov 19;95(22):1718-21.

• Chromosomal aberrations in patients with head and neck squamous cell carcinoma do not vary based on severity of tobacco/alcohol exposure.

Singh B, Wreesmann VB, Pfister D, Poluri A, Shaha AR, Kraus D, Shah JP, Rao PH. 

BMC Genet. 2002 Nov 14;3:22. Epub 2002 Nov 14.

• Genome-wide appraisal of thyroid cancer progression.
•  
• Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B.
•  
• Am J Pathol. 2002 Nov;161(5):1549-56.

• Refractory chronic sinusitis: evaluation of symptom improvement after Denker’s procedure.
•  
• Wreesmann VB, Fokkens WJ, Knegt PP.
•  
• Otolaryngol Head Neck Surg. 2001 Nov;125(5):495-500.

• Inflammatory pseudotumour (inflammatory myofibroblastic tumour) of the pancreas: a report of six cases associated with obliterative phlebitis.
•  
• Wreesmann V, van Eijck CH, Naus DC, van Velthuysen ML, Jeekel J, Mooi WJ.
•  
• Histopathology. 2001 Feb;38(2):105-10.

• Screening for genetic aberrations in papillary thyroid cancer by using comparative genomic hybridization.
•  
• Singh B, Lim D, Cigudosa JC, Ghossein R, Shaha AR, Poluri A, Wreesmann VB, Tuttle M, Shah JP, Rao PH.
•  
• Surgery. 2000 Dec;128(6):888-93;discussion 893-4.

Abstracts (Presentations at scientific meetings):

• Genome-wide screening for genetic prognostic factors in papillary thyroid carcinoma.
•  
• Wreesmann VB, Ghossein RA, Poluri A, Shaha AR, Tuttle RM, Shah JP Rao PH, Singh B.

Fifth International Conference on Head and Neck Cancer San Francisco, CA, July 2000.

• Hierarchical Clustering (HC): a Novel Approach to Evaluating the Prognostic Value of Laboratory Parameters in Patients (Pts) Undergoing Chemoradiation Treatment (CRT) for Advanced Laryngopharyngeal Carcinoma (LPC). 

Singh B, Pfister D, Wreesmann VB, Li R, Gogineni S, Bosl G, Hoffman RH, Shah JP, Rao PH. 

37th Annual Meeting of the American Society of Clinical Oncology; New Orleans LA, May 2001.

• Gain of 1q is unique to the tall cell variant of papillary thyroid cancer.

Wreesmann VB, Ghossein RA, Tuttle RM, Shaha AR, Robbins R, Shah JP, Rao PH, Singh B. 

73rd annual meeting of the American Thyroid Association, Washington D.C. November 2001.

• MUC1 is a target of 1q amplification and pertains a grave clinical prognosis in papillary thyroid cancer. 

Wreesmann VB, Sieczka E, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Shah JP, Rao PH, Ghossein RG, Singh B. 

Annual Meeting of the New York Head and Neck Society, New York, NY, March 2002.

• Genome wide screening identified gains and losses as independent prognostic variables in patients with head and neck squamous cell carcinoma (HNSCC). 

Singh B, Wreesmann VB, Thaler HT, Shi W, Shah JP, Shaha AR, Kraus DH, Boyle JO, Pfister D, Rao PH. 

38th Annual Meeting of the American Society of Clinical Oncology; Orlando, Fl May 2002.

• p53 inactivation by human papillomavirus (HPV) in Fanconi anemia associated squamous cell carcinoma. 

Kutler DI, Goberdhan A, Wreesmann VB, Giampietro PF, Auerbach AD, Singh B. 

The Sixth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer; Washington D.C.; October 2002.

• Identification of novel prognostic factors in head and neck squamous cell carcinoma. 
•  
• Wreesmann VB, Shi W, Thaler HT, Shah JP, Shaha AR, Kraus DH, Boyle JO, Pfister D, Rao PH, Singh B. 

7th symposion on Research in Head and Neck Cancer; Dusseldorf, Germany, September 4-6 2003.

• Molecular profiling of aggressive papillary thyroid cancer: prognostic significance of MUC1 alterations. 

Wreesmann VB, Sieczka E, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein RA, Singh B. 

7th symposion on Research in Head and Neck Cancer; Dusseldorf, Germany, September 4-6 2003.

• Chromosomal aberrations in Fanconi anemia-associated squamous cell carcinomas differ from sporadic squamous cell carcinomas from the general population. 

Kutler DI, Rao PH, Wreesmann VB, Goberdhan A, Ngai I, Huvos AG, Giampietro PF, Levran O, Pujara K, Diotti R, Auerbach AD, Singh B. 

15th annual Fanconi Anemia Research Fund scientific symposium, Houston TX, Oct 2003.

• Molecular classification of Fanconi anemia(FA)-associated head and neck squamous cell carcinoma (HNSCC) using oligonucleotide microarrays. 

Kutler DI, Ganly I, Wreesmann VB, Goberdhan A, Ngai I, Huvos AG, Giampietro PF, Levran O, Pujara K, Diotti R, Auerbach AD, Singh B. 

15th annual Fanconi Anemia Research Fund scientific symposium, Houston TX, Oct 2003.

•  
• Genotyping follicular cell-derived thyroid neoplasia: a CGH study of 150 cases.

Wreesmann VB, Ghossein RA, Socci N, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B. 

Sixth International Conference on Head and Neck Cancer, Washington DC, August 2004.

• Downregulation of Fanconi anemia genes in sporadic squamous cell carcinomas of the head and neck. 

Wreesmann VB, Estilo C, Eisele DW, Singh B, Wang SJ. 

208th meeting of the Netherlands Society of Otolaryngology-Head and Neck Surgery, Utrecht, April 7th 2006.

• Extracapsular nodal spread does not predict outcome in clinically node negative oral cavity squamous cell carcinoma. 

Wreesmann VB, Ghossein RA, Carlson D, Ganly I, Palmer F, Montero P, Shah JP, Patel SG. 

AHNS 2013 Annual Meeting, April 10 & 11, 2013, Orlando Florida.

• Minor (<2mm) extracapsular spread is not an adverse predictor of outcome in metastatic squamous cell carcinoma of the oral cavity. 

Wreesmann VB, Ghossein RA, Carlson D, Ganly I, Palmer F, Montero P, Shah JP, Patel SG. Presented at the AHNS 2014 Annual Meeting, July 2014, New York, New York.

Books, Chapters:

• Molecular Biology as applied to Head and Neck Oncology

Wreesmann VB, Singh B.

Stell and Maran's Textbook of Head and Neck Surgery and Oncology

Fifth Edition

Chapter, edited by John Watkinson and Ralph Gilbert

• Molecular-Cytogenetic Characterization of Head and Neck Cancer: Identification of molecular prognostic factors and targets of therapy

Wreesmann VB, Singh B.

Book, Amsterdam 2004

Reviewed in: Head and Neck: Volume 29, Issue 1, pages 82–83, January 2007

• Open Conservation Surgery for Laryngeal Cancer

Wreesmann VB, Ganly I

Scott-Brown's Otorhinolaryngology and Head and Neck Surgery, Eighth Edition

Chapter 27

CRC Press, Taylor-Francis Group, June 12th, 2018

• Molecular Oncology

Wreesmann V.B.

Self-Assessment in Head and Neck Surgery and Oncology, First Edition

Chapter 21

Elsevier 2014

Research grants:

Netherlands Cancer Institute “Startgeld” Grant 2008

Project: Fanconi anemia in head and neck cancer

Principal investigators: Wreesmann VB, van den Brekel MW, Balm AJM, Vens C.

Amount granted: 300.000 euro

Dr. Enriqueta Felip ist Expertin für thorakale Onkologie. Sie spezialisiert sich auf Lungenkrebsbehandlung und klinische Studien. Ihren Abschluss in Medizin und ihre Promotion erhielt sie an der UAB. Dr. Felip leitete Forschungen zur Verbesserung der Chemotherapie, Entwicklung neuer Therapien, Einsatz von Immuntherapie und zum Verständnis von Resistenz gegen zielgerichtete Behandlungen.

Von 2017 bis 2021 war sie Vorstandsmitglied der IASLC und von 2019 bis 2021 Vizepräsidentin der SEOM. 2015 erhielt sie den ersten ESMO Women for Oncology Award. Dr. Felip hat zahlreiche begutachtete Fachartikel und Buchkapitel verfasst. Sie ist bekannt für ihre Führungsrolle in internationalen Onkologie-Gesellschaften und in der klinischen Forschung.